Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BKT14T00 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 5.85 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
5.70 6.00 5.85 5.85 5.85
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.58 -6.11 -7.00 6
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 5.85 GBX

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Investors    Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
16/11/202222:53Midatech Pharma (MTPH) sees 10-fold increase1,993
03/3/202221:35 Midatech Pharma Plc10
24/1/202119:14Midatech Pharma 4
30/4/201920:51Midatech Pharma (MTPH) One to Watch 2
03/1/201712:41Midatech Pharma PLC181

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Top Posts
Posted at 08/12/2022 08:20 by Midatech Pharma Daily Update
Midatech Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 5.85p.
Midatech Pharma Plc has a 4 week average price of 5.85p and a 12 week average price of 5.85p.
The 1 year high share price is 23.25p while the 1 year low share price is currently 5.85p.
There are currently 98,493,413 shares in issue and the average daily traded volume is 87,200 shares. The market capitalisation of Midatech Pharma Plc is £5,761,864.66.
Posted at 11/7/2022 21:09 by criticalthinker1
17 March 2022



Midatech Pharma PLC

("Midatech" or the "Company")

Exercise of Warrants and Issue of Equity

Total Voting Rights

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has received a notice of exercise of warrants over 26 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an exercise price of £10.00 per share.

Hmmm

Posted at 28/6/2022 07:57 by kingston78
Does anyone know whether this company has sufficient cash this year? The share price is at an all time low. Is the company going to raise funds by way of a placing?
Posted at 10/6/2022 06:33 by manual dexterity
https://www.investegate.co.uk/midatech-pharma-plc--mtph-/rns/mtx110-study-to-be-presented-at-ispno-2022/202206100700083120O/

Midatech Pharma PLC
MTX110 Study to be Presented at ISPNO 2022

https://www.investegate.co.uk/midatech-pharma-plc--mtph-/rns/retirement-of-chairman-and-proposed-new-chairman/202206100700083736O/

New Chairman. Same chairman as Sareum Holdings plc.

Posted at 01/6/2022 14:04 by manual dexterity
Certainly with the cash element I would categorise both MTPH and EVG as similar and very interesting in their pipeline. Both share prices have been demolished and there is some overlay between the two.

However BOTH have very interesting pipelines.

https://www.proactiveinvestors.co.uk/companies/news/983834/midatech-pharma-rockets-on-cancer-fast-track-by-the-food-and-drug-administration-983834.html

Midatech Pharma PLC (AIM:MTPH) soared 32% to 13.5p after its MTX110 treatment for recurrent glioblastoma, a form of cancer, was given fast track designation by the Food and Drug Administration.

The drug-delivery technology company said the fast track process will facilitate the development and accelerate the review of treatments for serious conditions.

"Receiving Fast Track designation for MTX110 is an important milestone for the development of the drug as it demonstrates the need for novel and effective treatment options for this currently universally fatal disease," Dmitry Zamoryakhin, chief scientific officer, said.

Posted at 01/6/2022 13:55 by manual dexterity
Indeed he is. MTPH has fallen from around the 60p levels so assuming last placing was at 28p per share to raise £10million there will be some interest around these levels.
Posted at 01/6/2022 12:35 by kingston78
In August 2020 the share price had spiked to over 80 p. At its recent low of 10 p only a few days ago I did consider to buy some more shares but I did not because I didn't want to put too much money in one share. In retrospect I should have added.

Nevertheless, I think the share price has potential to go much higher from here.

Posted at 27/5/2022 13:24 by ssrmb
Kingston, on their website under Investors and share price info.
Posted at 27/5/2022 08:55 by kingston78
Where can you find out its share price in the US market?
Posted at 14/4/2022 11:39 by guy gibson
Midatech Pharma PLC

14 April 2022

14 April 2022

Midatech Pharma PLC

("Midatech" or the "Company"")

Receipt of NASDAQ Notice

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 13 April 2022, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares (the "Depositary Shares"), each representing five ordinary shares of the Company, for the 30 consecutive business days beginning 2 March 2022, the Company no longer meets the minimum bid price requirement.

The Notification Letter has no immediate effect on the listing of the Depositary Shares, and they will continue to trade on The NASDAQ Capital Market under the symbol "MTP."

In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until 10 October 2022 (the "Compliance Period"), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Depositary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be eligible for an additional grace period of 180 calendar days provided that the Company satisfies NASDAQ's initial listing standards for listing on The NASDAQ Capital Market, other than the minimum bid price requirement, and provides written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If the Company does not regain compliance during the initial grace period and is not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from The NASDAQ Capital Market. In that event, the Company may appeal such determination to a hearing panel.

The Company intends to monitor the bid price of its Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods.

The Company's business operations are not affected by the receipt of the Notification Letter.

The Company's ordinary shares are listed on the AIM Market of the London Stock Exchange, and the Notification Letter does not affect the Company's compliance status with such listing.

Posted at 09/6/2020 17:07 by mubz
https://www.marketscreener.com/MIDATECH-PHARMA-PLC-19157045/news/Midatech-Pharma-Letter-to-Deyan-Spiridonov-re-Midatech-30744197/

What is interesting is that this chap at Paul Hasting law firm- Deyan P. Spiridonov is a member of the firm's Mergers & Acquisitions practice. So have Secura Bio done this in order to trash MTPH share price and then put in a hostile bid to takeover


Please be advised that in the event that Secura Bio refuses to withdraw its purported termination notice, Midatech and Midatech Limited will vigorously pursue any and all available remedies, including claims for monetary damages based on Secura Bio's intentional wrongdoing.

Midatech and Midatech Limited also reserve all rights in law and equity against Secura Bio and its agents, including, without limitation, the right to pursue tort claims (and a recovery of fees and costs in the UK) resulting from Secura Bio's intentional efforts to cause harm to and to adversely affect Midatech's market position.

Midatech Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
MTPH
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221208 09:40:24